Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Researchers Focus on New Strain of Hydrilla Found Thriving in the Connecticut River


News Image

Greg Bugbee, a scientist with the Connecticut Agricultural Experiment Station, says the new invader has begun to replace the native eelgrass that provides a critical habitat for fish, mussels and other aquatic life. It has also begun to clog tributaries and coves along the river.

Hydrilla is well-known for invading lakes, ponds and waterways, especially across the southeastern U.S. But experts with the Weed Science Society of America (WSSA) say a new strain of the weed has now been found along a 70-mile portion of the 400-mile-long Connecticut River.

Hydrilla is the most widespread of the 19 aquatic weeds on the federal noxious weed list. It also represents a significant ecological and economic risk. That’s especially true for the environmentally rich Connecticut River, which begins on the Canadian border, spans four states and empties into the Long Island Sound.

The river has a major impact on the region and its economy. It supports fish, birds and other wildlife; farms, fisheries, marinas and other businesses; and the recreation and water needs of millions of residents who live and work nearby.

First discovered in 2016, the new hydrilla strain is spreading quickly. Recent surveys show the infestation has produced dense mats of floating hydrilla biomass that now cover nearly 1,000 acres of the river. And the impact is already being felt.

Greg Bugbee, a scientist with the Connecticut Agricultural Experiment Station, says the new invader has begun to replace the native eelgrass that provides a critical habitat for fish, mussels and other aquatic life. It has also begun to clog tributaries and coves along the river – making them impassible to motorboats used for touring, fishing and other water sports. The hydrilla engulfs propellor blades and causes engines to stall – a problem researchers faced firsthand as they conducted their survey of the river.

Bugbee says the new strain is genetically distinct from hydrilla found elsewhere, with differences in how it grows and reproduces. It is hardy and tolerates a wide range of growing conditions. Unlike other hydrilla strains in the U.S., it has yet to be observed producing potato-like tubers that can be buried in the sediment of rivers, lakes and ponds.

That may offer a control advantage, Bugbee says, since tubers can be hard to locate and remove and can sprout after remaining dormant for many years. By comparison, the new strain seems to spread primarily through axillary and basal turions – budlike nodules on the plant’s stem that can break off and root where they drop.

There are still lots of unknowns, though. Scientists don’t yet know how this genotype is best controlled. They also don’t know whether it can harbor neurotoxin-producing algae that can kill eagles, ospreys and coots – something that occurs among the warm-weather hydrilla found in the southeastern U.S. There is also great concern that this strain of hydrilla could be spread to other bodies of water by boats, canoes, kayaks and other sports equipment that can transport small fragments of the weed to new locations.

Fortunately, work is actively underway by various stakeholders to fill the information gap. One of the many agencies engaged in that effort is the U.S. Army Corps of Engineers, particularly at their Engineer Research and Development Center in Vicksburg, Mississippi. Michael Greer, the Corps’ program manager for aquatic nuisance species research, says his team is working closely with local, state and regional groups and is spearheading several initiatives that are already underway or on the horizon:

  •      It has funded a nationwide effort to expand what we know about the genetics of hydrilla – identifying the various strains of the invader, determining their range and measuring the extent of their infestation.
  •      It has funded research to explore the biology of the new Connecticut River variant and to conduct lab studies to determine how the nuisance species responds to the herbicides registered for control of aquatic weeds.
  •      It is working with partners from across the region to plan a Connecticut River field study that will serve as a proof of concept in how best to control the new genotype and restore the important ecological and economic benefits of the river.

“In effect, we’re writing a ‘book of knowledge’ that will capture the life history of this new strain, how it spreads and how to manage it effectively,” Greer says. “We hope to bring what we learn from our research into a real world setting and build a body of best management practices.”

To Learn More

  •      Explore a map of the Connecticut River Basin.
  •      Watch a video describing the hydrilla invasion on the Connecticut River.
  •      Read the Connecticut Agricultural Experiment Station’s report on hydrilla and other aquatic plants on the Connecticut River.
  •      Explore the five-year hydrilla management plan for the Connecticut River developed in 2020 by the Northeast Aquatic Nuisance Species Panel.
  •      Visit the Connecticut River Conservancy to find out more about hydrilla and the steps each of us can take to help slow its spread.

About the Weed Science Society of America

The Weed Science Society of America, a nonprofit scientific society, was founded in 1956 to encourage and promote the development of knowledge concerning weeds and their impact on the environment. The Society promotes research, education and extension outreach activities related to weeds, provides science-based information to the public and policy makers, fosters awareness of weeds and their impact on managed and natural ecosystems, and promotes cooperation among weed science organizations across the nation and around the world. For more information, visit http://www.wssa.net. The Aquatic Plant Management Society (APMS) is a national affiliate of WSSA.

EDITORS: Photos to support this press release can be downloaded from the WSSA website at https://wssa.net/credit-lines-for-hydrilla-photos.

Share article on social media or email:

Red Nucleus (“RN”) Expands Medical Communications Business Unit, Acquires AlphaGroup Medical Communications, LLC (“AlphaGroup” or the “Company”)


RN, a premier provider of strategic learning and development, scientific services and advisory, medical communications solutions, and market access and commercialization services exclusively for the life sciences industry, announced that it has acquired AlphaGroup, renowned for delivering leading scientific, medical affairs, and outcomes communication services for the pharmaceutical, biotech, and medical device/diagnostic industries. The Company’s services are high science, with over half its employees possessing advanced scientific degrees. AlphaGroup has expansive therapeutic expertise in oncology, virology, transplantation, immunology, rare diseases, gene therapy, and cardiology.

AlphaGroup, founded in 2005 by Stephen Douthwaite, provides a focused set of scientific and medical communications solutions centered on key medical activities throughout a product’s life cycle, beginning in pre-clinical development and spanning through FDA approval, product launch, and continued marketing efforts. The Company brings expertise in the areas of scientific medical communications (including manuscript, abstract, and poster development and strategic publication planning), medical affairs communications (including MSL tools, interactive educational and training tools, slide decks, publications, and KOL engagement), and health economics and outcomes research (HEOR), real world evidence (RWE), and payer communications. AlphaGroup brings new clients and extended services to the combined business.

Mike Smith, AlphaGroup Group Managing Director, said “Our commitment to delivering the highest quality communication services in the industry remains our top priority and was at the forefront of our decision to join Red Nucleus. Their industry reputation, global scale, and infrastructure to support our ongoing rapid growth made this a natural fit for our team and for our clients.”

“We are excited to be joining an organization that shares our core values of precision, integrity, and passion, and we look forward to collaborating closely with the rest of the medical communications business unit within RN to bring extended capabilities to our clients,” AlphaGroup Chief Strategy Officer Ed Shifflett adds.

“As internal and external collaboration grows across the pharmaceutical industry, winning agency partners will demonstrate true integration and a world class customer experience. AlphaGroup extends our Medical Communications capabilities across publications and medical affairs and brings exciting new services within the HEOR and RWE space,” adds Philip McCrea, Global President, Medical Communications at Red Nucleus.

“We are elated AlphaGroup has joined the Red Nucleus family as we continue our relentless drive to bring differentiated value to our clients across the product life cycle as we execute on our strategy of providing capability coverage from molecule to market,” said Red Nucleus CEO Ian Kelly.

The transaction closed in December 2022.

For more information, please contact

Media Contact:

Kelly Curtin

kcurtin@rednucleus.com

(917) 880-3449

About Red Nucleus

We are a global strategic partner with decades of experience across the entire life sciences product life cycle. We excel in providing our clients unique insights and efficiencies to support their journey to improve health outcomes and ultimately the quality of people’s lives. Our “red thread” weaves together a full suite of products and services from advisory, scientific, market access, medical communications, and learning and development that leads our life sciences clients to accelerated transformational success.

Share article on social media or email:

Icosagen Chooses Genedata Biologics to Digitalize Recombinant Antibody Discovery


News Image

“Since many of the biopharma and biotechs we work with as a CRDMO also use Genedata, it makes it even easier to exchange data with our customers,” said Mart Ustav Jr., Ph.D., Chief Scientific Officer of Icosagen.

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Icosagen, a research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals, has deployed Genedata Biologics® to digitalize and automate their recombinant antibodies discovery services in Europe and the U.S.

“We were looking for a solution with out-of-the-box functionality tailored for large molecule R&D and chose Genedata Biologics because it has everything we need to digitalize our antibody discovery and protein manufacturing operations,” said Mart Ustav Jr., Ph.D., Chief Scientific Officer of Icosagen. “Since many of the biopharma and biotechs we work with as a CRDMO also use Genedata, it makes it even easier to exchange data with our customers. We are also very pleased with Genedata’s support and global presence, which gives us local access to support our operations both in Europe and the U.S.”

Icosagen Cell Factory has custom-tailored services from discovery, hit-to-lead finding, pre-clinical candidate selection, up to early-stage clinical candidate development to provide recombinant antibodies and proteins to the biopharmaceutical and biotechnology industry. Genedata Biologics is used to automate and digitalize the full end-to-end discovery process at Icosagen, streamlining library generation, phage display selection and B-Cell screening, cloning and expression, IgG reformatting, lead characterization and developability assessment, candidate selection, and manufacturing along with cell line development.

“When I first met Genedata scientists at a conference, I was impressed with their deep level of understanding of antibody discovery processes, and their suggestions on how Icosagen could increase throughput and improve R&D operational efficiency,” said Joan Teyra, Ph.D., Principal Scientist at Icosagen. “This expertise was confirmed during deployment and roll-out of the Genedata platform. Genedata is helping us to get up and running with spot-on suggestions on how to best streamline our processes and improve data quality.”

“We are excited that Icosagen, a distinguished CRDMO, has chosen Genedata Biologics to digitalize their antibody operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Since Genedata Biologics is purpose-built for biotherapeutics and the platform of choice among top biopharma and biotech companies, more and more CRDMOs are adopting our platform to streamline operations and more easily share information with their biopharma customers.”

About Icosagen CRDMO

Icosagen is a research-driven contract research, development and manufacturing organization for biopharmaceutical, and biotechnology industries, focused on the production of functional recombinant proteins and antibody discovery. Icosagen’s unique CRDMO concept allows seamless transitions from transient R&D milligrams into stable high-producing cell lines and GMP manufacturing in several hundred-liter scale. Project and molecule know-how therefore stays in one single facility with one team and under one legal framework.

http://www.icosagen.com

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn | Twitter | YouTube

________________________________________

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence in Gosselies, Belgium


Catalent enables fully integrated cell therapy services — from our iPSC expertise in Düsseldorf, Germany, to process and analytical development in Gosselies, to clinical and commercial manufacturing in Gosselies and Princeton, New Jersey — all under one CGMP umbrella.

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies, in Gosselies, Belgium.

The new state-of-the-art facility will be one of the largest in the world, with 60,000 square feet (5,600 square meters) of dedicated cell therapy manufacturing space housing multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing through to late-stage clinical and commercial-scale supply. The facility has been designed to be EMEA and FDA compliant, with Grade B and C suites to support high-throughput processes and accommodate bioreactor-scale cell therapy manufacturing as well as on-site quality control (QC) laboratories and warehousing.

The newly completed facility is the latest addition to Catalent’s Gosselies campus, which already includes a 67,000-square-foot (6,200-square-meter) clinical manufacturing facility offering customers advanced clinical and commercial supply solutions. The overall Gosselies campus provides a one-stop shop, with process and analytical development labs, more than 20 CGMP grade B and C cleanrooms, dedicated QC labs, qualified person (QP) services, and warehousing.

“Catalent enables fully integrated cell therapy services—from our iPSC expertise in Düsseldorf, Germany, to process and analytical development in Gosselies, to clinical and commercial manufacturing in Gosselies and Princeton, New Jersey—all under one CGMP umbrella,” said Manja Boerman, Catalent’s President, BioModalities (Cell, Gene and Protein Therapies). “Together with our integrated plasmid DNA and viral vector services, the Catalent Cell & Gene Therapy network provides end-to-end services for development, scale up, and commercial launch of advanced therapies.”

The Gosselies campus also includes separate plasmid DNA (pDNA) development and manufacturing facilities. The clinical-scale pDNA facility, at 17,000 square feet (1,600 square meters), includes R&D, process development, QC labs, and multiple CGMP production suites. The commercial-scale pDNA facility, at 32,400 square feet (3,010 square meters), offers large-scale manufacturing.

About Catalent Cell Gene Therapy

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Planetary Scientist Dr. Alan Stern Announces Call for Mission Specialists for 2023 Titanic Expedition


Dr. Alan Stern, Chief Exploration Officer at World View and Associate Vice President, Space Sector at the Southwest Research Institute

Dr. Alan Stern Planetary Scientist while on OceanGate Expeditions 2022 Titanic Expedition

“I’m completely convinced that there will be a day when there are ocean explorers of celestial bodies like Europa, Triton, Titan, Enceladus, Pluto.” – Dr. Alan Stern

Earth’s oceans remain the least explored and understood, yet most impactful ecosystems on the planet. With a longitudinal study of the Titanic, OceanGate Expeditions is working to change that. Planetary scientist Dr. Alan Stern joined OceanGate Expeditions’ 2022 Titanic Expedition as a Mission Specialist. Dr. Stern brought a unique set of qualifications to the Mission Specialist role: he has led NASA’s New Horizons mission to Pluto and the Kuiper Belt since its inception in 2001 and is scheduled to participate in a 2023 Virgin Galactic suborbital research mission. He is currently Chief Exploration Officer at World View and Associate Vice President, Space Sector at the Southwest Research Institute. Dr. Stern shared his perspectives on the parallels between exploration in space and our deep oceans after his experience diving to the Titanic with OceanGate Expeditions.

“Fewer people have been to the Titanic than to space. It is both an archaeological expedition and a scientific one. The experience included the emotional highs of exploration and deep reflection as we remembered those lost on that cold, unforgiving night in April 1912. From fascination with OceanGate, Inc.’s amazing Titan submersible technology and the operational prowess of the OceanGate Expeditions crew, to sublime feelings of a lifetime accomplishment that, until a few months ago, I never considered possible,” said Dr. Stern in summarizing his 2022 Titanic diving experience.

“Being one of fewer than 250 people to come face-to-viewport with Titanic and the amazing biodiverse marine ecosystem that has now formed out of that tragedy is something I will always remember. I wasn’t just a passenger on the dive, either. As a Mission Specialist, I supported the study of the Titanic by collecting water column samples, communicating with the surface team throughout the dive, and filming the wreck and surrounding marine life. I even piloted the sub. I am still in awe of the experience. What a special opportunity it was, and one I hope to carry forward to show others what humans can do when they dream big and strive to accomplish those dreams. As a result of new private sector entrants like OceanGate Expeditions, we are now witnessing the very earliest days of what is likely to become an unparalleled era of exploration by humans, across the deep ocean, just like in space,” says Dr. Stern.

“What’s more, we have discovered that oceans of water are common in our solar system. I’m completely convinced that there will be a day when there are ocean explorers of celestial bodies like Europa, Triton, Titan, Enceladus, Pluto; after all, from what we know, all those ocean worlds out there that are begging for this type of advanced submersible technology,” continues Dr. Stern.

OceanGate Expeditions’ longitudinal study of the Titanic and surrounding areas will continue in 2023 with the support of citizen explorers who serve as Mission Specialists. Aspiring Mission Specialists interested in supporting the 2023 Titanic Expedition should contact OceanGate Expeditions for qualifications, availability, and additional details. Visit https://oceangateexpeditions.com/tour/titanic-expedition/ to learn more.

OceanGate Expeditions also recently announced the coffee table book, “Titanic Expedition: A Crewed Submersible Expedition to Explore the World’s Most Famous Shipwreck.” The limited release photographic account of the 2021 Titanic Expedition, with exclusive bonus photographs from the 2022 Titanic Expedition, is authenticated with a numbered holographic emblem and comes signed by OceanGate Expeditions chief submersible pilot, Stockton Rush, and 38 time Titanic diver and Titanic expert, PH Nargeolet. To learn how to purchase from only 324 limited edition books visit https://oceangateexpeditions.com/shop/2021titanicphotobook/.

###

OceanGate Expeditions

Media Inquiries | Lisa Dreher | lisa.dreher@oceangateexpeditions.com | +1 425-442-1301

Expedition Inquiries | Kyle Bingham | kyle.bingham@oceangateexpeditions.com | +1 425-595-6343

Investor Inquiries | Bob Shuman | robert.shuman@oceangatexpeditions.com | +1 425-595-5017

Business Inquiries | Bob Shuman | robert.shuman@oceangatexpeditions.com | +1 425-595-5017

Planetary Scientist, Dr. Alan Stern, shares the parallels between exploration in space and exploration of our deep oceans.

ABOUT OCEANGATE EXPEDITIONS

OceanGate Expeditions Ltd., is dedicated to direct human exploration of the undersea world. Not satisfied with scratching the surface of the ocean near the shoreline, OceanGate Expeditions charters manned submersibles to create expeditions at depths far deeper than can be reached with SCUBA. The organization conducts undersea expeditions to explore and document the 95% of the seafloor that man has never visited including iconic shipwrecks, hydrothermal vents, deep-sea canyons, and uncommon biological events around the world. These expeditions, to depths approaching 4,000 meters (13,123 feet), provide rare opportunities for citizen scientists to observe the mysteries of the deep sea and expand our understanding of our home, Earth, the blue planet. Visit http://www.oceangateexpeditions.com.

Follow OceanGate Expeditions on: YouTube | Instagram | Facebook | Twitter | LinkedIn

ABOUT OCEANGATE FOUNDATION

OceanGate Foundation is an independent 501(c)(3) organization that advances understanding of the ocean by providing grants in support of scientific and archaeological marine research, with an emphasis on innovative technologies such as human-occupied submersibles; and supporting efforts to engage and inspire explorers, researchers, civic leaders, and others in the public who share an interest in understanding the ocean. The foundation is the primary philanthropic partner of OceanGate Expeditions. Visit http://www.oceangatefoundation.org.

Share article on social media or email:



Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce


First-of-its-kind technology from Cellesce creates consistent patient-derived organoids for large scale drug screening

We’re excited to bring our domain expertise and intellectual property to Molecular Devices, together maximizing impact for customers in revolutionizing drug discovery and unlocking the full potential of human-relevant 3D biology research.

Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the acquisition of Cellesce Ltd (“Cellesce”) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening.

Drug efficacy and toxicity testing often rely on immortalized cell lines or animal models that don’t closely mimic complex human biology. This can lead to inaccurate predictions of a drug’s potential and extended drug development timelines. However, a number of retrospective studies confirm a high degree of similarity between the phenotype and genotype of a PDO and an original patient tumor, showing that if a drug worked on the PDO, it was 90 percent likely to work on the patient. This acquisition of Cellesce affirms Molecular Devices’ commitment to investing in 3D biology technologies that transform the drug discovery process and drive development of novel therapeutics.

“By combining Cellesce’s expertise in producing industrial-scale PDOs with Molecular Devices’ market-leading end-to-end solutions for automated organoid screening, we will enable customers to accomplish advanced 3D biology research with a commercial offering that’s never been available before from one provider,” said Susan Murphy, President of Molecular Devices. “This enabling technology will make over 100,000 compound primary screens with PDOs a reality and will accelerate industry adoption of organoids.”

Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development — all at a scale unmatched by any commercial technology available today. The company’s quality-assured, patented bioprocess workflow and unique bioreactors have been proven to increase productivity 20- to 60-fold.

“Molecular Devices has the capability, reputation, reach, and resources to ensure that the Cellesce technology can be further developed, and used to its full potential,” said Vicky Marsh-Durban, CEO of Cellesce. “We’re excited to bring our domain expertise and intellectual property to Molecular Devices, together maximizing impact for customers in revolutionizing drug discovery and unlocking the full potential of human-relevant 3D biology research.”

For more information on the promise of organoids for advanced drug discovery, visit http://www.moleculardevices.com.

About Molecular Devices, LLC.

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe. Visit Molecular Devices at http://www.moleculardevices.com.

About Cellesce

Based in Cardiff, Cellesce is a biotechnology company that has developed a patented bioprocessing technology for the growing on and expansion of organoids. Cellesce is focused on the supply of standardized and well characterized cancer organoids for large-scale applications such as compound screening, especially for high throughput screening requirements, where significant quantities of reproducible batches are required. Visit Cellesce at http://www.cellesce.com.

# # #

Share article on social media or email:

Amana Global Partners closes its oversubscribed inaugural life sciences venture fund AGP Ventures LP


Sajal Jagdish Heda (R) and Talal Marwan Al Ajou (L)

AGP Ventures LP provides an opportunity for family offices and institutional investors to invest alongside industry leaders in life sciences.

AGP Ventures LP is an early-stage life science venture fund, incorporated in the Cayman Islands, investing in disruptive technologies across segments like Genomics, Gene and Cell Therapies, Digital Health, Imaging, Diagnostics, AI, MedTech, Precision Medicines and others.

AGP Ventures LP provides an opportunity for family offices and institutional investors to invest alongside industry leaders in life sciences. The fund opens-up over 75 sought-after companies syndicate via combination of both high quality hard to access institutional level funds and direct investments in Americas and Europe. “AGP platform gives investor an ability to access few of the most exciting and disruptive investment opportunities duly vetted by our exceptional team” said Sajal Heda, General Partner.

Managed by a team with combined life sciences and investment experience of 150+ years, the fund has global footprint with presence in Boston, New York, London, Riyadh, Dubai, Mumbai, and Taipei. Fund has an “information advantage” from the extensive network of corporates, venture managers and academia in the life sciences industry. “With Limited Partners from Asia, Middle East and Europe, we are creating bridges between continents and pioneering regional eco-systems” said Talal Al Ajou, General Partner.

AGP team has nuanced expectations of limited partners. “We differentiate ourselves in the industry by encouraging our limited partners to engage in therapeutic areas which are personal for them” said Peter Savas, Venture Partner. The Fund has already invested in five early-stage companies solving for the unmet clinical needs in areas like dopamine transporter brain imaging agent, multiplex gene editing and multiple precise genetic modifications for xenotransplantation, creating novel proteins with non-standard amino acids, revolutionize biopsy real-time assessment and engineered TCR-T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations.

About Amana Global Partners

Amana Global Partners is a Cayman Island incorporated early-stage life sciences venture platform that invests alongside corporate venture groups, venture firms and top-tier investors with core thesis to invest in disruptive technologies and other fast growing life sciences sub-segments. Firm is co-founded by Sajal Jagdish Heda and Talal Marwan Al Ajou and has exceptional investment team with venture partners as Peter Savas and Paul Sekhri and advisory committee of notable industry experts.

Share article on social media or email:

A Strain Development Strategy to Enhance Screening, Process Development and Scale-Up, Upcoming Webinar Hosted by Xtalks


Through this webinar, the speaker wishes to highlight the importance of an efficient strain development strategy in order to reduce the timelines and the costs associated with product development.

Any current Good Manufacturing Practice (cGMP) E.coli program must be based on a solid strain development strategy. This thought led to the development of Cytovance’s Keystone Expression System® to provide a robust, high-yield E.coli strain to support cGMP manufacturing of a biologic. Cytovance’s elaborate toolbox enables creation and evaluation of multiple strains simultaneously. Although the workflow is standardized, it is versatile and flexible enough to accommodate unique requirements from companies, with cutting-edge technology. All of the offering is based on peer-reviewed literature published by leaders in the industry, which provides an intellectual property (IP)-free platform that is comprised of elements that are familiar to regulatory agencies. All of the strains are also created to fit into a robust, platform high-cell density fermentation process, that is designed for efficient scale-up into a Single-Use (SUF) or Stainless (SIP) fermenter.

Through this webinar, the speaker wishes to highlight the importance of an efficient strain development strategy in order to reduce the timelines and the costs associated with product development. The Keystone Expression system® and the toolbox generated in-house allows for simultaneous strain construction and screening. Through the course of the screening process, the simple but powerful SDS-PAGE is used for evaluating the expression levels of the strains, which negates the need for other sophisticated methods in earlier stages of the project. Once the top strains have been evaluated, in-house liquid chromatography–mass spectrometry (LC-MS) is used onsite to confirm the identity of the biologic prior to scale-up of the fermentation process.

Register for this webinar to learn more about protein expression and strain development strategies for effective product development.

Join Hari Priya Parameshwaran, PhD, Scientist, PD Upstream/Strain Development, R&D Services, Cytovance Biologics, for the live webinar on Tuesday, December 13, 2022, at 12pm EST (5pm GMT/UK).

For more information, or to register for this event, visit A Strain Development Strategy to Enhance Screening, Process Development and Scale-Up.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Quarterly scientific journal, Science Reviews


Science Reviews - Biology will appear online and in print, pays honorariums to authors of the best articles

Science Reviews – Biology will appear online and in print, pays honorariums to authors of the best articles

We encourage high-quality reviews and research articles, and to do this, we publish the best article free of charge in each issue and also pay a honorarium to its authors. Science Reviews – Biology exists both online and as a paper journal to ensure that published articles are never lost.

A new quarterly scientific journal launched, Science Reviews – Biology, is an international, multi-disciplinary, peer-reviewed open access journal that publishes reviews and research articles in the field of biology such as physiology, microbiology, genome editing, stem cell therapy, and more. The journal is published online and as a Canadian print journal (ISSN 2816-9107) with free delivery to authors.

“We encourage high-quality reviews, research articles and publications, and to do this, we publish the best article free of charge in each issue and also pay a honorarium to its authors,” said M. Zilberman, founder of Science Reviews – Biology. “Unlike many other open access journals, Science Reviews – Biology exists both online and as a paper journal to ensure that published articles are never lost.”

Science Reviews – Biology publishes reviews and research papers in the field of biology on topics such as physiology, microbiology, genome editing, stem cell therapy, and more. The journal’s goal is to encourage scientists to publish high-quality papers highlighting advances in the various areas of biology in which they are experts in. Recent articles published include, “Recent insights into the use of invertebrates as indicators of habitat quality” by Rae Osborn, PhD, “CRISPR/Cas9, a decade of genome editing tools to fix the DNA” by Lúcia Santos, PhD, and others.

Science Reviews – Biology charges around five to seven times lower article processing fees compared to other open access journals, and waives processing fees and pays a $300 honorarium per issue to the author of one outstanding article, selected by the editorial board. In the latest July-September issue, this honorarium was awarded to Saboor Ahmad, PhD candidate and Jianke Li, PhD authors of the article, “New insight into phosphoproteome research improves the in-depth understanding of honey bee biology”.

Science Reviews – Biology does not require authors to format articles submitted, as the formatting is done entirely by journal’s editors. This also ensures high quality layout and presentation, and saves the authors’ time for scientific research and other activities.

Unlike most academic journals, Science Reviews – Biology pays reviewers for their work, speeding up the review and decision process, and resulting in a submission to publication timeline of 3-4 weeks.

Science Reviews – Biology is currently accepting manuscripts for the next issue, which will be published in January 2023, online and in print. The deadline to submit manuscripts for the October-December issue is December 23, 2022.

For more information, please visit ScienceReviews.info.

Share article on social media or email: